Fusing two cells to solve one problem
In 1975, César Milstein and his postdoctoral researcher Georges Köhler fused two different kinds of cell, an antibody-producing white blood cell and a myeloma cancer cell, to create what became known as a hybridoma: a cell line that combined the antibody-producing cell’s ability to make one specific, precisely targeted antibody with the cancer cell’s ability to divide indefinitely. The result solved a problem that had limited antibody research and medicine for decades, the inability to produce a large, stable, identical supply of an antibody targeting one exact molecular feature, called an epitope, rather than the mixed, variable batch of different antibodies the immune system normally generates in response to any one threat. Their technique meant a laboratory could, for the first time, manufacture unlimited quantities of a single, precisely defined antibody rather than relying on the naturally occurring variety produced inside a living animal.
The chemistry behind the fusion
The fusion process itself relied on specific, deliberately chosen chemistry: polyethylene glycol to encourage the two cell types’ membranes to merge, and a selective growth medium called HAT that allowed only the successfully fused hybrid cells to survive and multiply while the unfused parent cells died off. Each surviving hybridoma cell line, once isolated, could then be grown indefinitely, with every descendant cell producing the identical antibody as its hybridoma ancestor, which is where the term monoclonal, meaning derived from a single cloned cell, comes from. Milstein patented the production method and went on to hold three further related patents, and the technique’s name, hybridoma, was coined not by Milstein or Köhler themselves but by another researcher, Leonard Herzenberg, during a sabbatical spent in Milstein’s own laboratory shortly after the original discovery.
From lab tool to Nobel Prize
The hybridoma technique has held up as a foundational tool across immunology and medicine for half a century, earning Köhler, Milstein and Niels Kaj Jerne the 1984 Nobel Prize in Physiology or Medicine for the underlying work on antibody specificity and production. The core method, fusing an antibody-producing cell with an immortal cancer cell line, remains recognisably the same process used to generate laboratory antibodies today, even as the antibodies themselves have been re-engineered for human use. Diagnostic techniques built directly on monoclonal antibodies, including Western blotting and immunohistochemistry, became standard laboratory tools precisely because a monoclonal antibody reliably targets one defined molecular feature, giving researchers a level of specificity that the older, naturally variable antibody mixtures could not offer.
The mouse-antibody problem
What the original 1975 technique could not solve on its own was the problem of using mouse-derived antibodies safely in human patients, since a human immune system tends to recognise mouse antibody proteins as foreign and mount its own immune response against them, weakening or eliminating the treatment’s effect. That gap was closed only later, when Gregory Winter’s team developed humanisation techniques in 1988, grafting the specific mouse-derived binding region responsible for recognising the target onto an otherwise human antibody framework, sharply reducing the immune rejection problem. Without that additional development, the therapeutic use of monoclonal antibodies in people would have remained far more limited than it eventually became, since the original hybridoma method by itself produced antibodies well suited to laboratory and diagnostic use but not yet safe for repeated treatment in human patients.
From cancer wards to a pandemic
The practical reach of monoclonal antibodies now extends across cancer treatment, autoimmune disease and infectious disease response. Approved cancer therapies including rituximab, trastuzumab and pembrolizumab target specific molecules on cancer cells or on the immune system itself, while infliximab and adalimumab, targeting a signalling molecule called TNF-alpha, are used to treat rheumatoid arthritis and inflammatory bowel disease. The same underlying technology was deployed rapidly during the COVID-19 pandemic: by 2020 the FDA had authorised monoclonal antibody treatments including bamlanivimab with etesevimab and casirivimab with imdevimab, with the United States government purchasing supplies worth 2.9 billion dollars, showing how a laboratory technique from 1975 could be adapted within months to a newly emerged disease once the underlying method was already mature and well understood.
Two breakthroughs, not one
This is worth the time for how directly it connects a specific, almost mechanical laboratory technique, fusing two kinds of cell, to a whole category of modern medicine most readers have likely encountered without realising the shared origin. It rewards attention to the gap between the 1975 discovery and its eventual therapeutic payoff, since the humanisation work needed to make these antibodies safe for repeated human use took over a decade of further research and is easy to overlook if the story stops at the Nobel Prize. Readers should come away understanding monoclonal antibodies not as a single invention but as a technique that required a second, separate breakthrough before it could reach the cancer wards and pharmacies where it is now routine. The through-line from a 1975 cell fusion to a 2020 pandemic treatment is unusually clear and worth following in full.